Elia

Advancing Autoimmune Disease Diagnostics Market: Surging Towards $9.84 Billion by 2030 with 7.2% CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, September 11, 2023
Health, Other Health, Systemic, Prevalence, Rheumatoid factor, Abbott Laboratories, ESR, Elia, BD (company), SLE, Approximation error, Creative Diagnostics, Compound annual growth rate, Incidence, Hospital, CRP, ANA, Thermo Fisher Scientific, Investment, PerkinElmer, Autoimmune disease, Growth, Diagnosis, Mindful Scientific Inc., Systemic scleroderma, Rheumatoid arthritis, Scleroderma, Reagent, Software, Medical device, Vaccine, Research

The global autoimmune disease diagnostics market is projected to reach a substantial value of $9.84 billion by the year 2030, exhibiting a robust Compound Annual Growth Rate (CAGR) of 7.2% from 2023 to 2030.

Key Points: 
  • The global autoimmune disease diagnostics market is projected to reach a substantial value of $9.84 billion by the year 2030, exhibiting a robust Compound Annual Growth Rate (CAGR) of 7.2% from 2023 to 2030.
  • The growth of the autoimmune disease diagnostics market is primarily fueled by the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases.
  • Key players in the autoimmune disease diagnostics market are directing their efforts toward developing, approving, and launching kits and assays for monitoring and diagnosing autoimmune diseases.
  • The report segments the autoimmune disease diagnostics market based on product type, test type, disease type, and end-user.

Unraveling the Autoimmune Disease Diagnostics Market to 2030: Global Burden, Key Tests, and Geographic Dynamics

Retrieved on: 
Friday, August 25, 2023
Systemic, Prevalence, Rheumatoid factor, Abbott Laboratories, ESR, Elia, BD (company), SLE, Approximation error, Creative Diagnostics, Compound annual growth rate, Incidence, Hospital, CRP, Thermo Fisher Scientific, Investment, ANA, PerkinElmer, Autoimmune disease, Growth, Diagnosis, Mindful Scientific Inc., Systemic scleroderma, Rheumatoid arthritis, Scleroderma, Reagent, Software, Medical device, Vaccine, Research

The growth of the autoimmune disease diagnostics market is primarily fueled by the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases.

Key Points: 
  • The growth of the autoimmune disease diagnostics market is primarily fueled by the increasing prevalence of autoimmune disorders, the growing emphasis on early diagnosis, and the rising awareness regarding autoimmune diseases.
  • Key players in the autoimmune disease diagnostics market are directing their efforts toward developing, approving, and launching kits and assays for monitoring and diagnosing autoimmune diseases.
  • The report segments the autoimmune disease diagnostics market based on product type, test type, disease type, and end-user.
  • This report is an invaluable resource for stakeholders navigating the dynamic landscape of autoimmune disease diagnostics.

Thermo Fisher Scientific Showcases New Clinical and Research Lab Solutions at AACC 2022

Retrieved on: 
Monday, July 25, 2022
Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, Genetics, Health Technology, Science, COVID-19, Biotechnology, Medical Supplies, Practice Management, Health, Transfer, Association, MAS, PPD, Diagnosis, Diversified Pharmaceutical Services, Thermo Fisher Scientific, Laboratory, U.S. FDA, Industry, Health, Elia, Scleroderma, Research, Genetics, Solution, Toxicology, Patheon, LC-MS/MS, TLA, American Association, Tsing Ma Control Area, COVID-19, Mindful Scientific Inc., Kingfisher, EUA, Fisher Scientific, Applied Biosystems, Infection, Â, AACC, Science, Patient, COVID, Ortho, FDA, Control, PCR, Invitrogen, Automation, Emergency Use Authorization, Medical device, Animal, Pharmaceutical industry

AACC 2022 Thermo Fisher Scientific Inc., the world leader in serving science, is showcasing innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics.

Key Points: 
  • AACC 2022 Thermo Fisher Scientific Inc., the world leader in serving science, is showcasing innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics.
  • During the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022), being held at the McCormick Place Convention Center in Chicago, July 2428, Thermo Fisher is exhibiting within booth #1413.
  • ***The Thermo Scientific Cascadion SM Clinical Analyzer, the Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay and the Thermo Scientific EliA RNA Pol III and EliA Rib-P are For In Vitro Diagnostic Use.
  • For more information on all the Thermo Fisher products and solutions exhibited at AACC 2022, please visit: thermofisher.com/aacc .

COVID-19 Diagnostics Market to be Worth $50.1 Billion by 2030 - Grand View Research, Inc.

Retrieved on: 
Wednesday, July 20, 2022
Antibody, Time, Diagnosis, COVID-19, Reagent, POC, Laboratory, Industry, Hospital, SAN, Pharynx, Elia, Research, LabCorp, USD, Adoption, CAGR, Roche, COVID-19 testing, Product, Disease, FDA, RT, Patient, Lists of countries and territories, Coronavirus, PCR, Revenue, Pharmaceutical industry, Animal, Fine chemical

SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- The global COVID-19 diagnostics market size is expected to reach USD 50.1 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- The global COVID-19 diagnostics market size is expected to reach USD 50.1 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to expand at a CAGR of 7.7% from 2022 to 2030.
  • The non-POC testing segment held a major market share of over 60.0% in 2021 and is expected to dominate the market during the forecast period.
  • Grand View Research has segmented the global COVID-19 diagnostics market on the basis of product and service, sample type, test type, mode, end-use, and region:
    COVID-19 Diagnostics Market - Product & Service Outlook (Revenue, USD Million, 2020 - 2030)

COVID-19 Diagnostics Market to be Worth $50.1 Billion by 2030 - Grand View Research, Inc.

Retrieved on: 
Wednesday, July 20, 2022
Antibody, Time, Diagnosis, COVID-19, Reagent, POC, Laboratory, Industry, Hospital, SAN, Pharynx, Elia, Research, LabCorp, USD, Adoption, CAGR, Roche, COVID-19 testing, Product, Disease, FDA, RT, Patient, Lists of countries and territories, Coronavirus, PCR, Revenue, Pharmaceutical industry, Animal, Fine chemical

SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- The global COVID-19 diagnostics market size is expected to reach USD 50.1 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- The global COVID-19 diagnostics market size is expected to reach USD 50.1 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to expand at a CAGR of 7.7% from 2022 to 2030.
  • The non-POC testing segment held a major market share of over 60.0% in 2021 and is expected to dominate the market during the forecast period.
  • Grand View Research has segmented the global COVID-19 diagnostics market on the basis of product and service, sample type, test type, mode, end-use, and region:
    COVID-19 Diagnostics Market - Product & Service Outlook (Revenue, USD Million, 2020 - 2030)

FDA Clears Thermo Scientific EliA RNA Pol III and EliA Rib-P Tests for Use in U.S.

Retrieved on: 
Thursday, June 9, 2022
FDA, Medical Devices, Other Health, Health, Genetics, Science, Applied Biosystems, Meta-analysis, Lupus, Arthritis, Research, Patheon, Autoantibody, Mayo Clinic College of Medicine and Science, SLE, Systemic scleroderma, Invitrogen, American College, Autoimmunity Reviews, Immunoglobulin G, PPD, Connective tissue, Scleroderma, FDA, Patient, Medical laboratory, RNA polymerase III, Fisher Scientific, BMC Medicine, Laboratory, Health, Review, Antibody, Diagnosis, Thermo Fisher Scientific, Autoimmunity, CTD, Efficiency, Systemic, Pharmaceutical Services Negotiating Committee, Elia, RNA polymerase, Mindful Scientific Inc., Medical device, Vaccine, Dermatology

Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Thermo Scientific EliA RNA Pol III and EliA Rib-P tests have been cleared by the U.S. Food & Drug Administration (FDA) for aiding in the diagnosis of Systemic Sclerosis (SSc; scleroderma) and Systemic Lupus Erythematosus (SLE).
  • [2] The EliA RNA Pol III test completes a criteria based EliA SSc panel and is the first fully automated RNA Polymerase test available in the U.S.
    A subset of SLE patients present with monospecific Ribosomal P antibodies.
  • The new EliA RNA Pol III and EliA Rib-P tests have been designed to improve the differentiation of SSc and SLE from other connective tissue diseases.
  • For more information on the Thermo Scientific EliA RNA Pol III and EliA Rib-P tests, please visit https://www.thermofisher.com/phadia .

The Phadia 2500+ Instrument Family Now Available in the U.S. for Autoimmune Testing

Retrieved on: 
Thursday, May 26, 2022
Other Health, Research, General Health, Pharmaceutical, Medical Devices, Hospitals, Genetics, Science, Biotechnology, Medical Supplies, Other Science, Health, Connective tissue disease, Thermo Fisher Scientific, Family, Autoimmunity, Applied Biosystems, Degenerative disease, Science, Patheon, PPD, Health, Automation, Coeliac disease, Rheumatoid arthritis, CTD, Research, Fisher Scientific, Immunoassay, Antiphospholipid syndrome, Elia, APS, Invitrogen, Mindful Scientific Inc., Diagnosis, Laboratory, West Pharmaceutical Services explosion, Medical device, Phadia

The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S.

Key Points: 
  • The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S.
  • The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.
  • This expanded capability of the Phadia 2500+ series of instruments allows for instrument consolidation and enables additional automation for EliA autoimmune diagnostics, aiding in the diagnosis of autoimmune diseases including Connective Tissue Disease (CTD), Antiphospholipid Syndrome (APS), Celiac Disease, Rheumatoid Arthritis, Autoimmune Liver Disease and Autoimmune Thyroid Disease.
  • The series of instruments includes the Phadia 2500 (ImmunoCAP analyzer), Phadia 2500EE (EliA analyzer) and Phadia 2500E (ImmunoCAP and EliA analyzer).

FDA Clears Thermo Scientific EliA SmD(P)-S Test For Use In U.S.

Retrieved on: 
Thursday, August 26, 2021
Nephritis, Laboratory, Arginine, Elia, Mindful Scientific Inc., Patheon, Pharmaceutical Services Negotiating Committee, Diagnosis, Thermo Fisher Scientific, Science, Serology, Research, Mixed connective tissue disease, Arthritis, LINK, Invitrogen, SLE, Antibody, Lupus, Degenerative disease, Applied Biosystems, Use, Patient, Fisher Scientific, CLIN, Medical laboratory, FDA, Mayo Clinic College of Medicine and Science, Medical device, Fine chemical

PORTAGE,Mich., Aug. 26, 2021 /PRNewswire/ --Thermo Scientific EliA SmDP-S test has been cleared by the U.S. Food & Drug Administration (FDA) for aiding the diagnosis of Systemic Lupus Erythematosus (SLE), the most common type of lupus.

Key Points: 
  • PORTAGE,Mich., Aug. 26, 2021 /PRNewswire/ --Thermo Scientific EliA SmDP-S test has been cleared by the U.S. Food & Drug Administration (FDA) for aiding the diagnosis of Systemic Lupus Erythematosus (SLE), the most common type of lupus.
  • This new test enhances specificity without sacrificing sensitivity, leading to a more precise diagnosis while also reducing the number of false positives1.
  • With the new EliA SmDP-S assay, clinicians can have greater confidence for differentiating SLE from mixed connective tissue disease, because of the improved immuno-chemical specificity.
  • For more information on the Thermo Scientific EliA SmDP-S test, please visit https://www.thermofisher.com/phadia
    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.

South Florida Restaurants Casa D'Angelo, Angelo Elia Pizza, Bar & Tapas And Angelo Elia Bakery Bar Tap The Gab Group As Agency Of Record

Retrieved on: 
Friday, August 16, 2019
Elia, Angelo, Italian cuisine

BOCA RATON, Fla., Aug. 16, 2019 /PRNewswire/ -- The Angelo Elia family of brands has appointed award-winning brand specialists The Gab Group as PR agency of record.

Key Points: 
  • BOCA RATON, Fla., Aug. 16, 2019 /PRNewswire/ -- The Angelo Elia family of brands has appointed award-winning brand specialists The Gab Group as PR agency of record.
  • Owned and operated by restaurateur and renowned Chef Angelo Elia, Casa D'Angelo Ristorante , Angelo Elia Pizza, Bar & Tapas and the Angelo Elia Bakery Bar feature authentic Italian cuisine with multiple locations throughout South Florida.
  • Through local and national public relations, The Gab Group will promote Angelo Elia restaurants as a culinary destination for true Italian dining from one of South Florida's most celebrated chefs.
  • "With traditional Italian recipes and perfection in ingredients, the authenticity of Angelo's cuisine is evidential in each and every bite."

CQ fluency's Global Director of Life Sciences, Clio Schils, Named as President to ELIA

Retrieved on: 
Wednesday, October 31, 2018
European League of Institutes of the Arts, Elia, Fluency, Human communication, Human behavior, Cognition

HACKENSACK, N.J., Oct. 31, 2018 /PRNewswire-PRWeb/ -- CQ fluency is pleased to announce and congratulate our Global Director of Life Sciences, Clio Schils , who will serve as the new President for Elia European Language Industry Association .

Key Points: 
  • HACKENSACK, N.J., Oct. 31, 2018 /PRNewswire-PRWeb/ -- CQ fluency is pleased to announce and congratulate our Global Director of Life Sciences, Clio Schils , who will serve as the new President for Elia European Language Industry Association .
  • Prior to this current leadership role with Elia, Clio served as Vice Treasurer and Vice President for Elia for the past two years.
  • Following the announcement, Clio Schils said: "It is a privilege for me to be elected as the new President of Elia.
  • CQ fluency is a language services company that specializes in culturally relevant translations for life science and healthcare in over 150 languages.